| First Author | Cornish VA | Year | 2003 |
| Journal | Pharmacogenomics J | Volume | 3 |
| Issue | 3 | Pages | 169-77 |
| PubMed ID | 12815365 | Mgi Jnum | J:84738 |
| Mgi Id | MGI:2669347 | Doi | 10.1038/sj.tpj.6500170 |
| Citation | Cornish VA, et al. (2003) Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenomics J 3(3):169-77 |
| abstractText | Arylamine N-acetyltransferases (NATs) are polymorphic xenobiotic metabolising enzymes, linked to cancer susceptibility in a variety of tissues. In humans and in mice there are multiple NAT isoforms. To identify whether the different isoforms represent inbuilt redundancy or whether they have unique roles, we have generated mice with a null allele of Nat2 by gene targeting. This mouse line conclusively demonstrates that the different isoforms have distinct functions with no compensatory expression in the Nat2 null animals of the other isoforms. In addition, we have used the transgenic line to show the pattern of Nat2 expression during development. Although Nat2 is not essential for embryonic development, it has a widespread tissue distribution from at least embryonic day 9.5. This mouse line now paves the way for the teratological role of Nat2 to be tested.The Pharmacogenomics Journal (2003) 3, 169-177. doi:10.1038/sj.tpj.6500170 |
